Pharma & Bio
Lifestyle
Will SamilPharmaceutical Benefit from TG-C’s Phase 3 Setback?…Revaluation of Rights to the ‘World’s First DMOAD’
The value of the exclusive domestic distribution rights for “Lorecivivint,” a new osteoarthritis drug secured by SamilPharmaceutical(000520), is expected to be reevaluated. This follows the failure of…
Technology
Diagnostics Rally Despite Kolon TissueGene Trial Setback [K-Bio Pulse]
Investor sentiment across South Korea’s pharmaceutical and life sciences sectors remained weak on July 22 following the Phase 3 setback for Kolon TissueGene’s osteoarthritis candidate TG-C.Kolon Tissu…
Lifestyle
NanoenTek,Inc. and NGeneBio Co., Ltd. Diagnostic Stocks Soar Amid Fallout from Kolon TissueGene, Inc.’s Clinical Trial Failure [Bio Spotlight]
On the 22nd, investor sentiment in the domestic pharmaceutical and life sciences sector Kolon TissueGene, Inc.(950160)continued to deteriorate in the wake of the failure of TG-C’s Phase 3 clinical tri…
Lifestyle
Controversy Over KOLON CORPORATION Inbosa’s “Fundamental Efficacy” Reignites... CEO Noh Moon-jong: “There Is No Problem with Its Efficacy”
Kolon TissueGene, Inc.(950160) Controversy surrounding the fundamental efficacy of TG-C (formerly Invossa), a cell-gene therapy for osteoarthritis, has reignited after the drug failed to demonstrate e…
Lifestyle
Investors Ask... What's Next After Record-Breaking Earnings? [In-Depth Look at Wise birds Inc. ③]
Wise birds Inc.(273060), which has successfully transformed itself from a traditional digital advertising agency into an AI-based advertising platform company, is drawing significant attention from th…
Lifestyle
The Key to the Era of Precision Medicine Is ‘Securing Real-World Clinical Data’… Macrogen, Inc. and NGeneBio Co., Ltd. Expected to Benefit
Cancer treatment is increasingly shifting toward a model where the patient’s tumor genes are analyzed to select the most appropriate therapy. Consequently, the key factor determining the competitivene…
Lifestyle
[Blue Ocean Veterinary Medical Devices] ③ RecensMedical, Inc. Draws Attention with Veterinary Cooling Devices… Targeting a Niche Market
As medical technology advances, the treatment of human diseases is evolving toward “personalized” and “precision medicine.” Consequently, demand for personalized treatment and precision medicine is no…
Technology
HLB INC. Prepares for U.S. Commercialization Even Before Liver Cancer Drug Approval… Hires Staff for Insurance Coverage
Excerpts from Eleva Therapeutics’ job postings. They specify tasks such as securing U.S. insurance coverage for the combination therapy of riboceranib and camrelizumab, as well as for lirapugratinib. …
Lifestyle
Kolon Plummets on TG-C Failure; NGeneBio Soars [K-bio pulse]
Shares of three Kolon Group affiliates plummeted Tuesday after Kolon TissueGene’s osteoarthritis cell and gene therapy TG-C—formerly known as Invossa—failed a late-stage U.S. clinical trial. Kolon Tis…
Lifestyle
KOLON CORPORATION’s Three Subsidiaries Plunge on ‘TG-C’ News… NGeneBio Co., Ltd. Rises [Bio Market Watch]
On the 21st, shares in the pharmaceutical and biotech sector plummeted to the daily limit-down following news of the clinical failure of “TG-C” (formerly Invossa), a cell-gene therapy for osteoarthrit…